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Received 24 January 2014; revised 1 April 2014; accepted 5 April 2014AbstractBackground: Prematurely menopausal women have a doubled lifetime risk of dementia and a 5-fold increased risk of mortality from neuro-
logical disorders, but the molecular mechanisms underlying these risks remain unclear. We hypothesized that ischemia-induced amyloidogenesis
may be enhanced in the hippocampus following prolonged loss of ovarian 17b-estradiol (E2), which could contribute to these phenomena.
Methods: The current study used a rat model of premature surgical menopause (10-week bilateral ovariectomy) with E2 therapy either initiated
immediately (short-term E2 deprivation (STED)) or delayed to the end of the ovariectomy period (long-term E2 deprivation (LTED)). One week
after continuous, subcutaneous E2 therapy, we subjected animals to 10-min global cerebral ischemia (GCI) to assess the effect of LTED on
ischemia-induced amyloidogenesis in the hippocampal CA1.
Results: The present study revealed that while hippocampal b-amyloid (Ab) is not typically enhanced following GCI, there is a rapid, robust
elevation of endogenous Ab in LTED females after GCI. In STED females, we observed that GCI attenuates and E2 maintains A Disintegrin and
Metalloprotease 10 (ADAM 10) expression in the hippocampal CA1, and concurrently, GCI increases and E2 decreases BACE1 levels in the
same region. Intriguingly, however, we observed a loss of E2 regulation of ADAM 10, ADAM 17, and BACE1 levels in the hippocampal CA1 of
LTED females, which provides mechanistic evidence for the enhanced post-ischemic Ab load following LTED. We also observed loss of E2
regulation of tau hyperphosphorylation in LTED females subjected to GCI.
Conclusion: Collectively, these studies partially explain the enhanced risk of dementia and mortality from neurological disorders seen in
prematurely menopausal women and support timely initiation of E2 therapy to yield maximum neurological benefit.
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Women that enter menopause prematurely, or before the
age of 40, due to bilateral oophorectomy incur a doubled
lifetime risk of dementia and a 5-fold increased risk of mor-
tality from neurological disorders.1,2 The molecular mecha-
nisms underlying the enhanced risks remain poorly
understood, but prolonged loss of the neuroprotective ovarian
steroid hormone 17b-estradiol (E2 or estrogen) is thought to
play a key role, as estrogen therapy administered at the time of
surgery and continued until the median age of naturalng by Elsevier B.V. Open access under CC BY-NC-ND license.
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have provided a potential clue as to why surgical menopause
may lead to an increased risk of dementia and mortality from
neurological disorders. Along these lines, recent work has
shown that the hippocampus sustains more damage from
global cerebral ischemia (GCI) following 10-week ovariec-
tomy (long-term E2 deprivation (LTED)); this includes pre-
viously unseen neuronal cell death in the hippocampal CA3
region, which is usually highly resistant to GCI, and a worse
cognitive outcome following GCI.4 Intriguingly, additional
work demonstrated that the hippocampus may become more
susceptible to non-ischemic stressors following LTED as well,
since the hippocampus of LTED female rats was also signifi-
cantly more damaged following exposure to b-amyloid
(Ab)(1e42), the most neurotoxic form of amyloid.4
Of the different types of dementia, Alzheimer’s disease
(AD) is the most common, and it is characterized by two
neuropathological hallmarks: senile plaques of Ab and
neurofibrillary tangles (NFTs) of hyperphosphorylated tau.5
Excess neural deposits of Ab and NFTs are neurotoxic,
causing extensive synapse loss and neurodegeneration, as well
as an irreversible cascade of progressive memory loss, psy-
chological disturbances, motor dysfunction, and eventually,
death.6 The amount of Ab present in the brain is largely
dependent on the processing of amyloid precursor protein
(APP), a Type I transmembrane protein that is sequentially
cleaved by enzymes to create intracellular and extracellular
fragments.7e9 APP has two main processing pathways: non-
amyloidogenic and amyloidogenic. During non-
amyloidogenic processing, APP is sequentially cleaved
within the Ab sequence domain by an a-secretase, such as A
Disintegrin and Metalloprotease 10 or 17 (ADAM 10 or
ADAM 17), followed by a gamma secretase enzyme com-
plex.7,9 As such, non-amyloidogenic APP processing pre-
cludes formation of Ab and produces three non-toxic
fragments.7,8 Conversely, during amyloidogenic processing,
APP is cleaved by the b-secretase Ab cleaving enzyme 1
(BACE1) prior to cleavage by the g-secretase machinery. This
results in the formation of the insoluble, neurotoxic 40e42
amino acid Ab protein. If not successfully cleared from the
brain, Ab monomers form oligomers that then aggregate into
extracellular deposits termed senile plaques.7
Intriguingly, E2 has been credited with a protective role
in AD.10 Observational studies revealed that postmeno-
pausal women exposed to exogenous estrogens mid-life had a
29%e44% decreased risk of dementia,11e13 and a recent study
suggested that longer cumulative lifetime durations of estro-
gen exposure, including both endogenous and exogenous
sources of E2, were associated with a lowered risk of AD, with
each additional month of E2 exposure translating to a 0.5%
decrease in AD risk.14 With respect to basic science studies,
E2 has also been repeatedly shown to protect against the
neuropathological hallmarks of AD both in vitro and
in vivo.10,15 For instance, E2 was found to prevent phosphor-
ylation of the microtubule-associated protein tau following
cerebral ischemia in rodents, which mitigates subsequent
formation of NFTs.15,16 Furthermore, exogenous E2 is wellknown to protect against Ab neurotoxicity,15,17,18 and brain-
specific E2 depletion was found to accelerate Ab deposition
and hinder Ab clearance in a transgenic mouse model of
AD.19 Collectively, these studies suggest that E2 tends to
reduce the neural load of Ab, and they corroborate post-
mortem studies, which found significantly reduced levels of
E2 in the brains of female AD patients, compared with age-
and gender-matched controls.19 In regard to the mechanism(s)
through which E2 modulates neural Ab, scientific evidence
supports E2 influence of both Ab deposition and Ab clearance.
Along these lines, E2 is purported to regulate expression of at
least two major proteins responsible for removal of neurotoxic
Ab: insulin degrading enzyme and neprilysin.20e24 With
respect to Ab deposition, several studies suggest that E2 may
regulate APP processing at several steps, thereby promoting
the non-amyloidogenic pathway. As evidence, BACE1, the
rate-limiting enzyme for Ab formation, has several estrogen
response elements (EREs) within its promoter region,25 and
E2 has been shown to decrease BACE1 expression both in
mixed neuronal cultures and in neurons in vivo.15,20,26,27
Conversely, E2 has also been hypothesized to regulate two
putative a-secretases ADAM 104,2730 and ADAM 17,26,31
which is also known as TNFa-converting enzyme (TACE).
While E2’s neuroprotective role in AD has been well
studied in vitro, E2’s neuroprotection from AD has not been
completely characterized in vivo, particularly considering the
development of AD-like neuropathology following GCI.
Furthermore, aside from a single observed decrease of nepri-
lysin expression in the brain 45 days post-ovariectomy,24 and
our lab’s recent finding of a switch to amyloidogenic APP
processing in the hippocampal CA3 region following GCI in
long-term ovariectomized females,4 the effect of LTED (sur-
gical menopause) on critical pathways affecting Ab load in
non-transgenic rodents is largely unknown. Along these lines,
the current study attempted to determine whether surgical
menopause enhanced amyloidogenesis in the hippocampal
CA1 following a stressor (GCI). Furthermore, the current
study also aimed to definitively characterize acute E2 regu-
lation of APP processing (ADAM 10, ADAM 17, and BACE1
expression) in the hippocampal CA1 following GCI and to
determine whether E2 regulation of APP processing is lost
following long-term ovariectomy, as these events could
mechanistically explain the enhanced risk of dementia and
mortality from neurological disorders observed in prematurely
menopausal women.
2. Methods2.1. AnimalsAll procedures were approved by the Georgia Regents
University Institutional Animal Care and Use Committee
(Animal Use Protocols: 09-03-174 and 2012-0474) and were
conducted in accordance with the National Institutes of Health
guidelines for animal research. Young adult (3-month-old)
female SpragueeDawley rats were utilized for these studies.
All animals were group housed on a 10 h/14 h lightedark
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Diet.2.2. Surgical menopause, estrogen therapy, and GCITo induce surgical menopause, all female rats were bilater-
ally ovariectomized under isoflurane anesthesia. At the time of
menopausal onset (short-term E2 deprivation (STED)) or 10
weeks later (LTED) the animals had subcutaneous, osmotic
mini-pumps (0.5 mL/h, 14-day release; Alzet, CA, USA)
implanted between their scapulae containing either placebo
(20% b-cyclodextrin) or 17b-estradiol (0.0167mg E2 in 20% b-
cyclodextrin) to mimic physiological E2 levels produced during
Diestrus I (10e15 pg/mL serum).16 As such, STED rats
modeled surgical menopause with immediate E2 therapy and
LTED modeled surgical menopause with delayed E2 therapy.
Oneweek after continuous treatment, GCI was performed using
4-vessel occlusion as described previously.32e34 Briefly, the day
before GCI, animals were anesthetized using intraperitoneal
chloral hydrate (350 mg/kg) or intraperitoneal ketamine/xyla-
zine (60 mg/kg and 8 mg/kg, respectively), and both vertebral
arteries (VA) were permanently occluded at the level of the alar
foramina via electrocauterization. Immediately following
bilateral VA occlusion, both common carotid arteries (CCA)
were carefully isolated and loosely ligated with suture thread
without interrupting blood flow. After a 24-h recovery period,
animals were re-anesthetized with light isoflurane (1%e4%),
and the bilateral CCA were occluded with hemostatic clips to
induce 10 min of complete forebrain ischemia. Animals which
lost their righting reflex within 30 s and whose pupils were
dilated and unresponsive to light during cerebral ischemia were
selected for the experiments. After 10 min, the clips were
removed, and reperfusion was confirmed before the wound was
sutured. During GCI, rectal temperature was maintained at
36.5 Ce37.5 C with a thermal blanket. Sham animals did not
receive pumps and underwent identical GCI surgical procedures
except that the CCAwere simply exposed but not occluded.2.3. Histological sample preparationFor brain harvesting, animals were deeply anesthetized
with isoflurane and transcardially perfused with 0.9% saline at
3 h or 24 h post ischemia-reperfusion, followed by fixation
with cold 4% paraformaldehyde in 0.1 mol/L phosphate buffer
(PB). Brains were post-fixed in the same fixative overnight at
4 C and cryoprotected with 30% sucrose in 0.1 mol/L PB, pH
7.4 for 24e36 h. Coronal sections (25 mm) were collected
throughout the entire dorsal hippocampus (w2.5e4.5 mm
posterior from Bregma, w100 sections per brain) for each
animal.2.4. Diaminobenzidine (DAB) stainingFor DAB staining, sections were incubated with 10%
normal horse serum in phosphate-buffered saline (PBS) con-
taining 0.1% Triton X-100 and 0.3% H2O2 for 1 h at room
temperature to block nonspecific surfaces. Sections were thenincubated with a single primary antibody: anti-PHF1 (1:1000,
gift from Peter Davies) or anti-Ab (1:100, MAB8768; Milli-
pore, Billerica, MA, USA) overnight at 4 C in PBS con-
taining 0.1% Triton-X100 and 1% horse serum. Afterward,
sections were washed with PBS containing 0.1% Triton-X100,
followed by incubation with secondary biotinylated horse anti-
rabbit/anti-mouse antibodies (1:500, Vector Laboratories, Inc.,
Burlingame, CA, USA) in the same buffer for 1 h at room
temperature. Sections were then washed and incubated with
ABC reagent for 20 min at room temperature. Finally, sections
were rinsed, mounted onto a slide, and incubated with DAB
reagent for 2e10 min, according to the manufacturer’s in-
structions (Vector Laboratories, Inc.). Following DAB incu-
bation, slides were washed briefly with distilled water,
dehydrated in increasing concentrations of ethanol, cleared in
xylene, and mounted using a xylene-based mounting medium.
Images were captured on an Axiophot-2 visible/fluorescence
microscope using an AxioVision 4Ac software system (Carl
Zeiss, Jena, Germany). Analysis was performed by counting
the number of immunopositive neurons per 250 mm length of
the medial CA1 pyramidal cell layer. A mean  SE was
calculated for each treatment group, which consisted of four to
seven animals each and three to five sections per animal.2.5. Immunofluorescence stainingCoronal sections were incubated with 10% normal donkey
serum for 1 h at room temperature in PBS containing 0.1%
Triton X-100, followed by incubation with primary antibody:
anti-ADAM10 (1:50, sc-25578; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), anti-ADAM 17/TACE (1:50, sc-
6416; Santa Cruz Biotechnology, Inc.), or anti-BACE1 (1:100,
AHB0241; Invitrogen, Carlsbad, CA,USA), overnight at 4 C in
the same buffer. After primary antibody incubation, sections
were washed for 3  10 min at room temperature, followed by
incubation with the appropriate combination of secondary an-
tibodies: Alexa-Fluor 488/568/647 donkey anti-rabbit/anti-
mouse/anti-goat (1:500; Invitrogen). Sections were then
washed with PBS containing 0.1%Triton X-100 for 3 10min,
followed by 2  5 min with 1 PBS and briefly with water.
Then, sections were mounted with water-based mounting me-
dium containing anti-fading agents.2.6. Confocal microscopyAll images were captured on an LSM510 Meta confocal
laser microscope (Carl Zeiss) using a 40 oil immersion
Neofluor objective (NA, 1.3) with the image size set at
1024  1024 pixels. The following excitation lasers/emission
filters settings were used for various chromophores: argon/2
laser was used for Alexa-Fluor 488, with excitation maximum
at 490 nm and emission in the range of 505e530 nm, HeNe1
laser was used for Alexa-Fluor 568 with excitation maximum
at 543 nm and emission in the range of 568e615 nm, and
HeNe2 laser was used for Alexa-Fluor 647 with excitation
maximum at 633 nm and emission in the range of
650e800 nm. The captured images were viewed and analyzed
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nation of negative controls confirmed the absence of nonspe-
cific immunofluorescent staining, cross-immunostaining, or
fluorescence bleed-through. Images were analyzed by
measuring the integrated density of fluorescent staining with
ImageJ analysis software (Version 1.45s; http://imagej.nih.
gov/ij/download.html, NIH, Bethesda, MD, USA) for each
animal (2e5 sections/animal), and a mean  SE was calcu-
lated from the data in each group (n ¼ 5e10 animals/group).2.7. Brain homogenization and protein extractionFor total protein extraction from the hippocampal CA1
region, rats were euthanized by rapid decapitation under deep
anesthesia 3 h or 24 h post ischemia-reperfusion. Once the
whole brains were removed, the hippocampi were dissected
from both sides of the hippocampal fissure, and the dorsal
CA1 regions were separated. CA1 hippocampal tissues were
immediately frozen in dry ice, and stored at 80 C until use.
Tissues were homogenized with a Teflon-glass homogenizer
in ice cold homogenization medium consisting of 50 mmol/L
HEPES (pH 7.4), 150 mmol/L NaCl, 12 mmol/L b-glycer-
ophosphate, 3 mmol/L dithiothreitol (DTT), 2 mmol/L so-
dium orthovanadate (Na3VO4), 1 mmol/L EGTA, 1 mmol/L
NaF, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 1%
Triton X-100, and inhibitors of proteases and enzymes
(0.5 mmol/L PMSF, 10 mg/mL each of aprotinin, leupeptin,
and pepstatin A). The homogenates were centrifuged at
15,000 g for 30 min at 4 C, and supernatants were collected
and stored at 80 C until use. Protein concentrations were
determined with a Modified Lowry Protein Assay Kit
(Thermo Scientific, Waltham, MA, USA), using bovine
serum albumin as a standard.2.8. Western blottingFor Western blotting, 20e50 mg of total hippocampal CA1
protein lysate were separated via 4%e20% SDS-PAGE. Pro-
teins were transferred to a polyvinylidene fluoride (PVDF)
membrane (Immobilon-P; Millipore), blocked for 3 h, and
incubated with 1 antibody against Ab Oligomers (1:500,
AB9234; Millipore), PHF-1 (1:1000, gift from Peter Davies),
Tau (1:200, sc-1995; Santa Cruz Biotechnology), or Amyloid
Precursor Protein C-Terminal Fragments (1:4000, A8717;
SigmaeAldrich, St. Louis, MO, USA) overnight at 4 C. a-
Tubulin (1:500, sc-5286, Santa Cruz Biotechnology) served as
a loading control. The membrane was then washed with Tween
20-PBS to remove unbound antibody and incubated with 2
antibody: Alexa Fluor 680/800 goat anti-rabbit/mouse IgG
(1:10,000; Invitrogen) or Alexa Fluor 680/800 donkey anti-
goat IgG (1:10,000, Invitrogen), for 1 h at room tempera-
ture. Bound proteins were visualized using the Odyssey Im-
aging System (LI-COR Bioscience, Lincoln, NE, USA), and
semi-quantitative analysis of the bands was performed using
ImageJ analysis software. To quantitate hippocampal protein
abundance, band densities of the indicated total proteins were
analyzed and expressed as ratios relative to either full-lengthprotein or a-tubulin signals, as appropriate, and a
mean  SE was calculated from each group for graphical
presentation and statistical comparison.2.9. Statistical analysisStatistical analysis was performed using two-way analysis
of variance (ANOVA), followed by a Student-Newman-Keuls
post-hoc test via NCSS software (NCSS, LLC., www.ncss.
com). Statistical significance was accepted at the 95% confi-
dence level ( p < 0.05). All data were expressed as
mean  SE.
3. Results3.1. Surgical menopause enhances development of
AD-related neuropathology in the hippocampal CA1
region following GCIWe first aimed to determine whether premature and chronic
loss of ovarian E2 would enhance the development of AD-like
neuropathology in the hippocampus following an ischemic
insult. To investigate, we utilized the STED and LTED animal
models, with immediate (STED) or delayed (LTED) E2 therapy,
and used GCI as the stressor. We first sought to determine
whether the hippocampal load of Ab was altered in LTED fe-
males subjected to GCI. DAB staining was used to visualize
endogenous neuronal Ab in the STED and LTED hippocampal
CA1 region of non-ischemic sham and ischemic (GCI) Pla- and
E2-treated animals. The results revealed a robust increase in
number of pyramidal cells immunopositive for intracellular Ab
oligomers 24 h post GCI in the hippocampal CA1 region of
LTED, but not STED, females (Fig. 1A: e, f and B). Further-
more, Western blotting analysis also revealed significantly
increased Ab oligomer formation in the hippocampal CA1 re-
gion of LTED female rats 24 h post GCI, relative to a-tubulin
expression (Fig. 1B), and this increase was not attenuated by
delayed E2 treatment in LTED females. These findings suggest
that neuronal Ab load is increased in long-term surgically
menopausal rats subjected to cerebral ischemia and that delayed
E2 therapy cannot prevent this event.
Since neurofibrillary tangles are another major neuropath-
ological hallmark of AD, we next chose to examine E2’s
ability to regulate the hyperphosphorylation of tau following
chronic loss of ovarian E2. Cerebral ischemia is a well-known
tauopathy.35e38 In fact, we previously demonstrated that GCI
induces significant hyperphosphorylation of tau 24 h post GCI
and that low-dose E2 pretreatment attenuates this event.16 We,
thus, hypothesized that E2’s regulation of tau hyper-
phosphorylation may be lost following LTED. To investigate,
we examined paired helical filaments (PHF) of microtubule-
associated tau phosphorylated at Ser 396 and Ser 404, two
residues implicated in human AD neuropathology. Results
revealed that both the number of PHF-immunopositive cells
(Fig. 2A) and PHF protein levels (Fig. 2B) were increased 24 h
after GCI (Fig. 2A: b, e and B), and 1 week of E2 pre-
treatment, initiated immediately following ovariectomy, was
Fig. 1. Post-ischemic b-amyloid (Ab) load is enhanced in the hippocampus
following long-term ovariectomy. (A) Representative DAB staining (top)
demonstrates Ab expression in the CA1 region 24 h post 10-min global ce-
rebral ischemia. Quantitative summary (bottom, means  SE, n ¼ 4e7 ani-
mals/group) indicates the number of Ab-positive neurons per 250 mm medial
CA1. (B) Western blotting shows Ab expression 24 h post 10-min global
cerebral ischemia in total CA1 hippocampal lysates of female rats treated with
placebo (Pla) or low-dose estrogen (E2) either immediately (STED) or 10
weeks (LTED) following bilateral ovariectomy. Quantifications of band den-
sities (means  SE, n ¼ 4e7 animals/group) are expressed as densitometric
ratios of Ab to a-tubulin. *p < 0.05, compared to sham; #p < 0.05, compared
to STED Pla; p^ < 0.05, compared to STED E2. Scale bar ¼ 50 mm.
Fig. 2. Estrogen regulation of ischemia-induced tau phosphorylation is lost
following long-term ovariectomy. (A) Representative DAB staining (top)
demonstrates expression of microtubule-associated protein tau phosphorylated
at Ser 396 and Ser 404 (paired helical filaments, PHF) in the hippocampal CA1
region 24 h after 10-min global cerebral ischemia. Quantitative summary
(bottom, means  SE, n ¼ 4e7 animals/group) indicates the number of PHF-
positive neurons per 250 mmmedial CA1. (B) Western blotting shows PHF and
total tau expression 24 h post 10-min global cerebral ischemia in total CA1
hippocampal lysates of female rats treated with placebo (Pla) or low-dose
estrogen (E2) either immediately (STED) or 10 weeks (LTED) following
bilateral ovariectomy. Tubulin is shown as a loading control. Quantifications of
band densities (means  SE, n ¼ 4e7 animals/group) are expressed as
densitometric ratios of PHF to tau. *p < 0.05, compared to sham; #p < 0.05,
compared to STED Pla; p^ < 0.05, compared to STED E2. Scale bar ¼ 50 mm.
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contrast, delayed E2 treatment was unable to mitigate the
phosphorylation of tau at these two pathological residues in
LTED rats (Fig. 2A: f and B), suggesting that E2 regulation of
tau phosphorylation is, indeed, lost following LTED.3.2. Surgical menopause leads to loss of a-secretase
expression in the hippocampal CA1 after GCITo better understand the mechanisms underlying the
marked elevation of endogenous Ab in LTED rats, we next
examined hippocampal CA1 expression of two putative a-secretases: ADAM 10 and ADAM 17, as well as the b-sec-
retase BACE1 (section 3.3). ADAM 10 and ADAM 17 are
thought to be the driving forces of non-amyloidogenic pro-
cessing of APP, and although some controversy exists
regarding which putative a-secretase is mainly responsible,9
recent studies have provided evidence that ADAM 10 is the
primary a-secretase and that ADAM 17 plays a more sec-
ondary role in the non-amyloidogenic processing of APP.39e41
In our studies, we searched for evidence of acute E2 regulation
Fig. 3. Hippocampal ADAM 10 expression is acutely regulated by global
cerebral ischemia and estrogen but dysregulated after long-term ovariectomy.
(A) Representative photomicrographs depict ADAM 10 expression in the
hippocampal CA1 of short-term E2-deprived (STED) and long-term E2-
deprived (LTED) female rats 3 h following 10-min global cerebral ischemia.
(B) Quantitative summary of data (means  SE, n ¼ 4e6 animals/group)
indicates the raw integrated density of ADAM 10 immunostaining in the
medial CA1. *p < 0.05, compared to sham; #p < 0.05, compared to STED
placebo (Pla); p^ < 0.05, compared to STED E2. Scale bar ¼ 50 mm.
Fig. 4. Hippocampal ADAM 17 expression is diminished after long-term
ovariectomy in the event of global cerebral ischemia. (A) Representative
photomicrographs depict ADAM 17 expression in the hippocampal CA1 re-
gion 3 h after 10-min global cerebral ischemia. Note that a marked reduction
in ADAM 17 expression was only observed in ischemic long-term ovariec-
tomized (LTED) females. (B) Quantitative summary of data (means  SE,
n ¼ 4e6 animals/group) indicates the raw integrated density of ADAM 17
immunostaining in the medial CA1. *p < 0.05, compared to sham; #p < 0.05,
compared to short-term E2-deprived (STED) placebo (Pla); p^ < 0.05,
compared to STED E2. Scale bar ¼ 50 mm.
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regulation of ADAM 10 and ADAM 17 expression following
LTED. As shown in Fig. 3, confocal microscopy revealed that
ADAM 10 expression was significantly down-regulated in the
hippocampal CA1 region 3 h post GCI (Fig. 3A: b, e and B)
and that immediate E2 replacement following ovariectomy
prevented this loss in STED females (Fig. 3A: c and B). LTED
placebo (Pla) animals had markedly decreased ADAM 10
levels 3 h following GCI, similar to STED Pla animals. Of
significant interest, however, delayed E2 therapy in LTED
animals could not prevent the post-ischemic loss of ADAM 10
in the hippocampal CA1 (Fig. 3A: f and B).
While recent literature touts ADAM 10 as the main a-
secretase responsible for the non-amyloidogenic processing
of APP,39,40 other studies maintain that ADAM 17 or TACE
plays a major role in the same process.42 Therefore, we also
examined expression of ADAM 17 following GCI and long-
term ovariectomy. In contrast to ADAM 10, there was no
ischemia-induced decrease of ADAM 17 expression in the
hippocampus 3 h post GCI in STED females (Fig. 4A: b and
B). Furthermore, there was no E2 regulation of ADAM 17
expression in the hippocampal CA1 region at the same time
point after ischemia (Fig. 4A: c and B). Following 10-week
ovariectomy, non-ischemic LTED sham animals displayed a
pattern for increased basal ADAM 17 immunostaining, but
this trend did not reach statistical significance. However,confocal microscopy did reveal a marked loss of ADAM 17
expression 3 h post GCI in long-term ovariectomized
(LTED) females, and importantly, delayed E2 therapy was
unable to prevent this loss (Fig. 4A: e, f and B). As a whole,
our data suggest that non-amyloidogenic processing of APP
may be significantly impaired in the event of ischemia
following long-term ovariectomy, as hippocampal CA1 region
expression of both a-secretases ADAM 10 and ADAM 17 are
significantly decreased upon exposure to ischemic stress in
long-term ovariectomized rats. Furthermore, the observed
impairment of non-amyloidogenic processing of APP suggests
that a switch to amyloidogenic processing of APP may occur
in LTED females in the event of ischemic stress.3.3. Surgical menopause enhances BACE1 expression
and promotes a switch to amyloidogenic processing of
APP in the hippocampal CA1 after GCISince the b-secretase BACE1 is thought to be the rate-
limiting step for Ab formation via the amyloidogenic pro-
cessing of APP,25 we next aimed to determine how GCI,
exogenous E2, and long-term ovariectomy influence BACE1
expression in the hippocampal CA1 region. Confocal micro-
scopy analysis revealed that neuronal BACE1 expression was
acutely up-regulated in the hippocampal CA1 region of STED
212 E.L. Scott et al.females 3 h following GCI and that this elevation was pre-
vented by pretreatment with low-dose E2 initiated at the time
of ovariectomy (Fig. 5A: aec and B). However, following
LTED, we observed a loss of E2 regulation of ischemia-
induced BACE1 expression in the hippocampal CA1 region
(Fig. 5A: e, f and B), suggesting that low-dose E2 is no longer
able to prevent the ischemia-induced increase of hippocampal
BACE1 following prolonged loss of ovarian E2. Furthermore,
we noted a modest increase in basal expression of BACE1 in
the hippocampal CA1 region of non-ischemic LTED sham
animals, but similar to changes observed in basal ADAM 17
expression, this trend did not reach statistical significance
(Fig. 5A: d and B). These results agree with the aforemen-
tioned a-secretase results, suggesting that non-amyloidogenic
processing of APP is significantly impaired and that amyloi-
dogenic processing of APP is significantly enhanced following
long-term ovariectomy (LTED), particularly in the event of
GCI.
In light of the evidence suggesting a post-ischemic switch
to amyloidogenic APP processing following surgical meno-
pause, we next decided to more closely examine the proteo-
lytic processing of APP. As discussed previously, APP
processing can be categorized as either non-amyloidogenic or
amyloidogenic. Non-amyloidogenic processing of APP occurs
through sequential cleavage by a- and g-secretases andFig. 5. Long-term ovariectomy enhances BACE1 expression in the hippo-
campal CA1. (A) Representative photomicrographs demonstrate BACE1
expression in the hippocampal CA1 3 h post 10-min global cerebral ischemia.
Note the elevated expression of BACE1 in long-term ovariectomized (LTED)
females. (B) Quantitative summary of data (means  SE, n ¼ 4e6 animals/
group) indicates the raw integrated density of BACE1 immunostaining in the
medial CA1. *p < 0.05, compared to sham; #p < 0.05, compared to short-term
E2-deprived (STED) placebo (Pla); p^ < 0.05, compared to STED E2. Scale
bar ¼ 50 mm.produces three non-toxic fragments: p3, sAPPa, and C83.7 In
contrast, amyloidogenic APP processing occurs through
sequential cleavage by b- and g-secretases and produces the
neurotoxic Ab protein, as well as two other fragments: sAPPb
and C99.7 To investigate changes in APP processing in the
current study, we performed Western blotting analysis for the
two APP C-Terminal fragments C99 and C83, which are
representative of amyloidogenic and non-amyloidogenic APP
processing, respectively, and we compared the C99/C83 ratio
in the hippocampal CA1 region among the different treatment
groups. As expected, the C99/C83 ratio was less than 1 in
STED sham animals, suggesting that non-amyloidogenic APP
processing predominates in the hippocampus under basal
conditions (Fig. 6). This ratio was modestly elevated (1.0) 24 h
following GCI in STED animals and returned to baseline if E2
therapy was administered immediately following ovariectomy
(Fig. 6), indicating that GCI promotes amyloidogenic and E2
promotes non-amyloidogenic processing of APP. While the
C99/C83 ratio remained less than 1 in LTED sham animals,
this ratio was significantly elevated (>1) in both LTED pla-
cebo- and LTED E2-treated females (Fig. 6). This observation
corroborates our a- and b-secretase data, suggesting that
following surgical menopause, GCI induces a major switch to
amyloidogenic APP processing in the hippocampal CA1 and
that delayed E2 therapy is unable to mitigate this event.Fig. 6. Long-term ovariectomy promotes a switch to amyloidogenic APP
processing in the hippocampal CA1 following global cerebral ischemia. (A)
Western blotting demonstrates C-Terminal fragments of amyloid precursor
protein (APP) 3 h following 10-min global cerebral ischemia in total CA1
hippocampal lysates of female rats treated with placebo (Pla) or low-dose
estrogen (E2) either immediately (STED) or 10 weeks (LTED) following
bilateral ovariectomy. C99 is a byproduct of b-secretase-mediated APP
cleavage, and C83 is a byproduct of a-secretase-mediated APP cleavage.
a-Tubulin is shown as a loading control. (B) Quantifications of band densities
(means SE, n ¼ 3e5 animals/group) are expressed as densitometric ratios of
C99 to C83. Note that C99/C83 ratios greater than 1 were only observed in
LTED females subjected to ischemia. *p < 0.05, compared to sham; p^ < 0.05,
compared to STED E2.
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The purpose of the current study was to test the hypothesis
that surgical menopause leads to enhanced amyloidogenesis in
the hippocampal CA1 region after ischemic injury and to
decreased sensitivity of the APP processing pathway to E2
regulation. Our study yielded several new findings, including:
1) acute regulation of the a-secretase ADAM 10 in the hip-
pocampal CA1 region by both GCI and E2, 2) evidence of an
ischemia-induced switch to amyloidogenic processing of APP
in the hippocampal CA1 region, 3) a robust increase in hip-
pocampal Ab load in LTED female rats after an ischemic
insult, and 4) a loss of E2’s ability to regulate post-ischemic
changes in ADAM 10, ADAM 17, BACE1, and PHF
following LTED. Collectively, these findings suggest that E2’s
ability to prevent post-ischemic hippocampal AD-related
protein induction is, indeed, lost following long-term
ovariectomy.
With respect to the first finding (acute regulation of
ADAM 10 by GCI or E2), expression of the a-secretase
ADAM 10 has been shown to be decreased by oxygen-
glucose-deprivation, chronic hypoxia, and chronic anoxia in
primary cortical neurons, neuroblastoma cells, and cerebral
microvascular smooth muscle cells, respectively, in vitro.43e45
However, this is the first study, to our knowledge, demon-
strating an acute loss of hippocampal ADAM 10 expression
following cerebral ischemia in vivo. Interestingly, E2 signaling
has been recently linked with modulation of ADAM 10 in the
brain. In fact, two green tea derivatives, ()-epigallocatechin-
3 gallate (EGCG) and octyl gallate, were recently reported to
reduce Ab plaque load in transgenic AD mouse models via an
ERa/PI3K/Akt signaling mechanism, which led to maturation
and increased a-secretase activity of ADAM 10.29,46 An
additional study revealed that administration of 100 mg/kg E2
to an ovariectomized, D-galactose-injected rat model of AD
led to elevation of ADAM 10, reduction of BACE1, and
alleviation of spatial memory deficits.27 The current study
corroborates these findings by showing that low, Diestrus I
levels of E2 are capable of preventing GCI-induced loss of
hippocampal ADAM 10 in vivo. Furthermore, our results
expand upon these findings by demonstrating E2 regulation of
ADAM 10 expression in wild-type, non-transgenic rodents,
suggesting that E2 may play a key role in endogenous non-
amyloidogenic processing of APP in the hippocampus. It
should be mentioned here that a single study which used a
longer (4-month) ovariectomy period, observed an increase in
ADAM 10 mRNA in the absence of ischemia.28 While the
current study did not find an elevation of ADAM 10 expres-
sion in non-ischemic LTED sham animals, it used a much
shorter ovariectomy period (10 weeks). Thus, these results are
not necessarily in disagreement.
The second novel finding of our study was evidence of a
post-ischemic switch to amyloidogenic processing of APP in
the hippocampal CA1 region following LTED. In particular,
we observed a loss of protein expression of both a-secretases
ADAM 10 and ADAM 17, an elevation of protein expression
of the b-secretase BACE1, and an increase in the C99/C83protein ratio in the hippocampal CA1 of LTED females sub-
jected to GCI. While neuronal expression of the a-secretase
ADAM 10 has not been previously studied in the context of
ischemia in vivo, neuronal expression of ADAM 17, or TACE,
has been demonstrated to be enhanced following ischemic
preconditioning.47,48 Since this suggests that up-regulation of
ADAM 17/TACE is a neuroprotective mechanism responsible
for the phenomenon of ischemic tolerance, down-regulation of
an a-secretase, like ADAM 17, in the hippocampus following
ischemic stress could be detrimental to neurons. As such, a
marked decrease in expression of two neuroprotective a-sec-
retases in LTED females after ischemia (both ADAM 10 and
ADAM 17) could partially explain the hippocampal hyper-
sensitivity to GCI-induced cell loss observed in LTED fe-
males.4,49,50 While exogenous E2 has been shown previously
to modulate expression of both ADAM 10 and ADAM 17
in vitro and in vivo,26,27,31 this is the first study to suggest that
ovarian-derived E2 may promote non-amyloidogenic pro-
cessing of APP following ischemic stress via modulation of
a-secretase expression in hippocampal neurons in vivo. Along
with the significant increase in the amyloidogenic C99/C83
APP fragment ratio and the significant increase in BACE1
expression in the hippocampal CA1 of LTED females sub-
jected to GCI, a robust loss of non-amyloidogenic ADAM10
and ADAM 17 expression suggests that prolonged loss of
ovarian E2 may promote a switch to amyloidogenic processing
of APP in the event of ischemia. This finding extends a recent
report by our laboratory, which described a post-ischemic
switch to amyloidogenic processing of APP in the hippo-
campal CA3 region of LTED females, which becomes hy-
persensitive to both GCI and Ab neurotoxicity following 10-
week ovariectomy.4 The current study demonstrates that this
process also occurs in the critical hippocampal CA1 region of
LTED females. Furthermore, it shows that E2 is capable of
regulating two putative a-secretases (ADAM 10 and ADAM 17)
in addition to its known regulation of the b-secretase BACE1.
These additional findings are particularly important because
they suggest that the post-ischemic switch to amyloidogenic
APP processing that occurs following LTED is not region-
specific. Along these lines, it will be important for future
studies to determine whether long-term ovariectomy only en-
hances stress-induced amyloidogenesis in the hippocampus or
if this event occurs in other critical regions of the brain, such
as the cerebral cortex.
The third major finding of the current study was an
increased Ab load in the hippocampal CA1 of LTED females
subjected to GCI. This observation corroborates the changes
seen in a-secretase expression, b-secretase expression, and the
C99/C83 ratio following ischemia in LTED females, sug-
gesting that the post-ischemic switch to amyloidogenic pro-
cessing of APP does, in fact, enhance amyloidogenesis in the
hippocampus of surgically menopausal females. Furthermore,
this finding agrees with our previous study, which observed a
switch to amyloidogenic APP processing and a resulting in-
crease in Ab immunoreactivity in the hippocampal CA3 re-
gion of LTED females following GCI.4 While not examined in
this study, it is possible that a loss of E2 regulation of Ab
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Considering that E2 has been shown to up-regulate both
neprilysin and insulin-degrading enzyme,20e24 as well as
induce microglial phagocytosis of Ab,51 it would be inter-
esting to determine whether long-term loss of ovarian E2 in-
creases post-ischemic hippocampal Ab load only through
enhancing amyloidogenesis or whether it hinders the clearance
of insoluble Ab as well. One concern is that premature sur-
gical menopause, which is associated with a doubled lifetime
risk of dementia,1 alone may enhance neurotoxic Ab deposi-
tion in the brain in the absence of ischemia. However, neither
the current study nor our previously published work4 found an
increase of Ab in the hippocampus of LTED sham animals.
Furthermore, an unrelated study found that the total hippo-
campal BACE1/ADAM 10 mRNA ratio, which reflects the
status of amyloidogenic processing of APP, was unchanged in
non-ischemic females ovariectomized for 4 months.28
Together, these studies suggest that LTED alone does not
promote a switch to amyloidogenic processing of APP and that
an acute stressor is required for hippocampal amyloidogenesis
to occur.
The fourth and final finding was a loss of E2 regulation of
post-ischemic changes in hippocampal ADAM 10, ADAM 17,
BACE1, and PHF following LTED. These results agree with
our previous study, which found a loss of E2 regulation of
BACE1 and PHF in the hippocampal CA3 region of LTED
females after ischemia.4 Furthermore, it extends the afore-
mentioned study to the critical CA1 region of the hippocam-
pus and shows, for the first time, that E2’s ability to regulate
a-secretase expression is lost following premature surgical
menopause. Importantly, this finding is also in agreement with
a growing body of literature that suggests low-dose E2 has a
decreased ability to regulate neural factors following long-
term ovariectomy.4,49,50,52e54,55e57 One important question is
whether enhanced post-ischemic development of AD-like
neuropathology in a region critical for learning and memory
would worsen neurocognitive outcome following an ischemic
insult. Indeed, our colleagues found that ischemic LTED fe-
male rats, which displayed an increased Ab load in the CA3
region of the hippocampus, performed worse on the Morris
water maze than their ischemic STED counterparts.4 This
suggests that the enhanced ischemia-induced AD-like neuro-
pathology seen in LTED female rats may further impair neu-
rocognitive functioning.5. Conclusion
The current study provides evidence that prolonged loss of
ovarian E2, through premature surgical menopause, could
predispose the female hippocampus to development of AD-
like neuropathology (increased hippocampal Ab and PHF) in
the event of ischemic stress. This could occur due to the loss of
E2’s ability to regulate post-ischemic changes in AD-related
proteins, such as the a- and b-secretases and the
microtubule-associated protein tau. As such, these detrimental
molecular changes could underlie the enhanced risk ofdementia and mortality from neurological disorders observed
in prematurely menopausal women.
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